How much does a box of Vemurafenib cost on the market?

Vemurafenib/Zobovo(Vemurafenib) is an oral small molecule targeted drug targeting the BRAF V600E mutation and is a BRAF kinase inhibitor. Its application is mainly concentrated in the treatment of melanoma patients who cannot be surgically removed or have metastasized. It is an important breakthrough in the field of precision treatment of melanoma in recent years. Vemurafenib inhibits the abnormally activated BRAF protein kinase signaling pathway, thereby reducing the growth and proliferation of tumor cells and improving patient survival. Compared with traditional chemotherapy, the emergence of this drug has significantly improved the treatment options for melanoma patients, and also promoted the development of personalized medicine for tumors.

In the Chinese market, the original drug vemurafenib has been officially launched and has been included in the medical insurance catalog. This has greatly improved the accessibility of drugs and significantly reduced the burden on patients. At present, the common specifications in the domestic market are 240mg*56 tablets, and each box sells for about 5,000 yuan. Compared with the high price when it was first launched, the price adjustment after medical insurance negotiations has greatly reduced the financial pressure on patients, especially those who take the drug for a long time.

If we look at the international market, the selling prices of different versions of vemurafenib vary greatly. For example, the original research version on the Turkish market has the same specifications of 240 mg and 56 tablets. Each box is priced at about more than 3,000 yuan. The price will change due to local pricing policies and exchange rate fluctuations. In addition, generic versions of drugs have been launched in some overseas countries and regions. The ingredients of the drugs are basically the same as the original drugs, and the efficacy and safety meet international drug quality requirements. For example, the generic version of Vemurafenib produced in Laos is priced at approximately RMB 2,000 for 56 tablets of 240 mg, which is lower than the original drug, providing an additional option for some patients without medical insurance support.

In general, vemurafenib not only provides a new treatment path for BRAF V600E mutant melanoma patients in clinical practice, but also forms a multi-level price system in the market with the emergence of medical insurance coverage and generic drugs to meet the needs of different countries and patient groups.

Reference: https://www.drugs.com/mtm/vemurafenib.html